CA2032169A1 - Methode de localisation et de traitement des tumeurs et complexes servant a cette fin - Google Patents

Methode de localisation et de traitement des tumeurs et complexes servant a cette fin

Info

Publication number
CA2032169A1
CA2032169A1 CA002032169A CA2032169A CA2032169A1 CA 2032169 A1 CA2032169 A1 CA 2032169A1 CA 002032169 A CA002032169 A CA 002032169A CA 2032169 A CA2032169 A CA 2032169A CA 2032169 A1 CA2032169 A1 CA 2032169A1
Authority
CA
Canada
Prior art keywords
polylysine
tumor
agent
complex
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002032169A
Other languages
English (en)
Inventor
Steven Kornguth
Patrick Turski
H. Ian Robins
Robert J. Nickles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2032169A1 publication Critical patent/CA2032169A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002032169A 1989-05-04 1990-05-02 Methode de localisation et de traitement des tumeurs et complexes servant a cette fin Abandoned CA2032169A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34735889A 1989-05-04 1989-05-04
US347,358 1989-05-04

Publications (1)

Publication Number Publication Date
CA2032169A1 true CA2032169A1 (fr) 1990-11-05

Family

ID=23363373

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002032169A Abandoned CA2032169A1 (fr) 1989-05-04 1990-05-02 Methode de localisation et de traitement des tumeurs et complexes servant a cette fin

Country Status (5)

Country Link
EP (1) EP0471790A4 (fr)
AU (1) AU628988B2 (fr)
CA (1) CA2032169A1 (fr)
FR (1) FR2646608A1 (fr)
WO (1) WO1990013256A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
DE102007059752A1 (de) * 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2277547A1 (fr) * 2009-07-20 2011-01-26 Merck Patent GmbH Conjugué d'epsilon-polylysine et son utilisation
GB201106742D0 (en) * 2011-04-20 2011-06-01 Spheritech Ltd Cross-linked poly-e-lysine
WO2013138696A1 (fr) * 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Complexes de zirconium-89, procédés de marquage de cellules, cellules marquées, kits et leurs procédés d'utilisation
GB2562004B (en) * 2012-04-20 2019-10-23 Spheritech Ltd Cross-linked poly-e-lysine particles
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
AU593611B2 (en) * 1986-02-14 1990-02-15 Nihon Medi-Physics Co., Ltd. High molecular compounds having amino groups, and their utilization
WO1989000052A1 (fr) * 1987-06-30 1989-01-12 Mallinckrodt, Inc. Procede permettant d'augmenter la securite de chelates de ligand metallique utilises comme agents d'imagerie de resonateurs magnetiques et comme agents de contraste de rayons x
JPH01176000A (ja) * 1987-12-30 1989-07-12 Nippon Mejifuijitsukusu Kk 放射性医薬品とその調製用高分子化合物

Also Published As

Publication number Publication date
AU5679490A (en) 1990-11-29
EP0471790A4 (en) 1992-07-08
FR2646608A1 (fr) 1990-11-09
AU628988B2 (en) 1992-09-24
EP0471790A1 (fr) 1992-02-26
WO1990013256A1 (fr) 1990-11-15

Similar Documents

Publication Publication Date Title
US5230883A (en) Method for localization and treatment of tumors using polylysine complexes
US5059415A (en) Method for diagnostically imaging lesions in the brain inside a blood-brain barrier
Deshpande et al. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice
TWI283178B (en) Method and kit for efficient radiolabeling of proteins with therapeutic radioisotopes
Jennewein et al. Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine
Deshpande et al. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent
Primus et al. Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen
Konda et al. Biodistribution of a 153Gd-folate dendrimer, generation= 4, in mice with folate-receptor positive and negative ovarian tumor xenografts
Unger et al. Magnetic resonance imaging using gadolinium labeled monoclonal antibody
AU672968B2 (en) Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
US5000935A (en) Treatment method utilizing transferrin-radioiodine conjugate
US5399338A (en) Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
JP2914737B2 (ja) 免疫試薬
McAfee et al. The localization of indium-111-leukocytes, gallium-67-polyclonal IgG and other radioactive agents in acute focal inflammatory lesions
EP0496074A1 (fr) Anticorps monoclonaux biotinylés, avidin et biotin pour la diagnose et la thérapie
CN114773433B (zh) 一种cd25靶向多肽、分子探针及应用
AU628988B2 (en) Method for localization and treatment of tumors and complexes therefor
CN115651063A (zh) 放射性核素标记的ptp多肽及其应用
US5223242A (en) Negatively charged specific affinity reagents
Kornguth et al. Preferential binding of radiolabeled poly-L-lysines to C6 and U87 MG glioblastomas compared with endothelial cells in vitro
EP0268707A2 (fr) Réactifs d'affinité spécifique portant une charge négative
Arano et al. Discriminated release of a hippurate-like radiometal chelate in nontarget tissues for target-selective radioactivity localization using pH-dependent dissociation of reduced antibody
EP0494247A1 (fr) Procedes de reduction de la retention non ciblee d'immunoconjugues et leurs metabolites.
Jalilian et al. Development of 111In-DTPA-human polyclonal antibody complex for long-term inflammation/infection detection
US6824759B2 (en) Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19931102